Company / Depreciation & Amortization
Sarepta Therapeutics Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$44.5M
FY2025
5-year range
$26.9M / $44.5M
FY2021-FY2025
Trend
+18.0%
vs FY2024
Sector context
#32 of 168
Health Care
What the data says
Sarepta Therapeutics's depreciation & amortization of $45M is higher than 81% of companies in the Health Care sector (FY2025). Depreciation & Amortization has fluctuated over the past 10 years, ranging from $6M in FY2016 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of +29.5%. Top quartile in the Health Care sector.
Remained stable around $45M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +18.3%
- 5-Year CAGR
- +29.5%
- 10-Year CAGR
- -
Sector benchmark
-79.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.5%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 18.0% year-over-year.
- Ranks #32 out of 168 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.5M | +18.0% |
| FY2024 | $37.7M | -15.0% |
| FY2023 | $44.4M | +65.0% |
| FY2022 | $26.9M | -29.2% |
| FY2021 | $38.0M | +210.5% |
| FY2020 | $12.2M | +51.3% |
| FY2019 | $8.1M | -33.9% |
| FY2018 | $12.2M | +51.3% |
| FY2017 | $8.1M | +44.2% |
| FY2016 | $5.6M | +6.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026